Discovery of New Commercially Valuable Antibiotics to Treat Bacterial Infection

Discuva’s platform screens thousands of small molecules to find new antibiotics that bacteria struggle to resist. This matters because common antibiotics are losing their power. Gram-negative bacteria, which cause severe hospital infections like sepsis and pneumonia, are especially hard to treat. Most new antibiotics are just tweaks of old ones, so resistance emerges quickly. Discuva’s approach identifies not only which molecules kill the bacteria, but also the specific genes that would let the bacteria fight back. That allows researchers to discard compounds with weak resistance profiles early, before investing years in development. If successful, the project could produce lead compounds that pharmaceutical companies will want to license and develop into actual drugs. The direct impact would be new treatments for infections that currently have few options. The less visible effect would be on hospital operations, surgical procedures, and cancer care—all of which depend on effective antibiotics to prevent post-treatment infections. Without new classes of antibiotics, routine medical care becomes riskier. Discuva’s platform is designed to keep the pipeline of genuinely novel antibiotics from running dry.